Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib [PDF]
PLoS ONE, 2022 BackgroundThis prospective, multisite, blinded, randomized, non-inferiority clinical study aimed to confirm the efficacy and safety of enflicoxib in the treatment of pain and inflammation associated with canine osteoarthritis.
Llorenç Badiella, Josep M Homedes
exaly +12 more sources
Pharmacology of enflicoxib, a new coxib drug: Efficacy and dose determination by clinical and pharmacokinetic‐guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model [PDF]
Veterinary Medicine and Science, 2022 Enflicoxib is a newly developed NSAID of the coxib class. The optimal therapeutic dose to be confirmed in the field studies was established using a combination of pharmacokinetic (PK) modelling and pharmacodynamic (PD) studies.
Josep M Homedes
exaly +7 more sources
Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months [PDF]
BMC Veterinary Research, 2021 Background Daxocox® [Ecuphar/Animalcare Group] contains the selective COX-2 inhibitor enflicoxib, approved in the EU for the treatment of pain and inflammation associated with osteoarthritis in dogs.
Josep M Homedes
exaly +8 more sources
A blinded, randomized and controlled multicenter field study investigating the safety and efficacy of long-term use of enflicoxib in the treatment of naturally occurring osteoarthritis in client-owned dogs [PDF]
Frontiers in Veterinary ScienceBackgroundEnflicoxib is a COX-2 selective NSAID shown to be efficacious and safe in the treatment of pain and inflammation associated with canine osteoarthritis (OA) in clinical studies of 6 weeks duration.ObjectiveThis prospective, multisite, blinded ...
Josep M Homedes
exaly +9 more sources
Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration [PDF]
Journal of Veterinary Pharmacology and Therapeutics, 2021 Abstract The pharmacokinetics of enflicoxib were evaluated in both a bioavailability study and a multi‐dose safety study in Beagle dogs. When administered at 8 mg/kg, the oral bioavailability (F) of enflicoxib was 44.1% in fasted dogs, but F increased to 63.4% under post prandial conditions. Enflicoxib is rapidly metabolised.
Josep M Homedes
exaly +6 more sources
Selective inhibition of cyclooxygenase‐2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood [PDF]
Journal of Veterinary Pharmacology and Therapeutics, 2022 Abstract Enflicoxib is approved for the treatment of pain and inflammation in canine osteoarthritis. The objective of this work was to assess the mechanistic basis of enflicoxib therapy investigating the COX inhibitory activity of enflicoxib (racemate), its enantiomers and its main metabolites using the canine whole blood assay.
Josep M Homedes
exaly +6 more sources
Enflicoxib for the long-term management of canine osteoarthritis—External validation of a population pharmacokinetic model in dogs with osteoarthritis [PDF]
Frontiers in Veterinary ScienceIntroductionEnflicoxib is a cyclooxygenase-2 (Cox-2) selective non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation in canine osteoarthritis (OA) and in soft and orthopedic surgery.
Josep M Homedes
exaly +6 more sources
Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6‐week randomised, controlled, blind, multicentre clinical trial [PDF]
Veterinary Record, 2022 Abstract Background Enflicoxib is a new COX‐2 selective NSAID intended for the treatment of pain and inflammation associated with canine osteoarthritis. Methods A prospective, multisite, blinded, randomised, controlled, parallel‐group field study was performed to determine the efficacy and safety of enflicoxib in canine osteoarthritis.
Josep M Homedes
exaly +4 more sources
Evaluation of the Genotoxic Potential of the Selective COX-2 Inhibitor Enflicoxib in a Battery of in vitro and in vivo Genotoxicity Assays. [PDF]
Drug Res (Stuttg), 2022 Abstract Aim Enflicoxib, a selective COX-2 inhibitor approved for the treatment of pain and inflammation associated with osteoarthritis in dogs (Daxocox® [Ecuphar/Animalcare Group]) was assessed for its genotoxic potential in a battery of in vitro and in ...
Guzmán A, Homedes J, Salichs M.
europepmc +5 more sources
Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. [PDF]
J Vet Pharmacol Ther, 2022 Abstract Robenacoxib is a veterinary‐approved non‐steroidal anti‐inflammatory drug (NSAID) of the coxib group. It possesses anti‐hyperalgesic, anti‐inflammatory and anti‐pyretic properties. Robenacoxib inhibits the cyclooxygenase (COX)‐2 isoform of COX selectively (in vitro IC50 ratios COX‐1:COX‐2, 129:1 in dogs, 32:1 in cats). At registered dosages (2
Lees P +5 more
europepmc +2 more sources